Irving Investors is an event driven equity fund that also participates in private investment opportunities. Irving looks at all areas of the market and focuses on high growth companies and disruptive technologies.
205 Detroit St
Colorado, United States
|2021-03-02||eGenesis||Series C||$125M||Alta Partners, Altium Capital, ARCH Venture Partners, Catalio Capital Management, Farallon Capital Management, Fresenius Medical Care Ventures, HBM Healthcare Investments, Invus Group, Khosla Ventures, Leaps by Bayer, LifeSci Venture Partners, Monashee Investment Management, Osage University Partners, Polaris Partners, Samsara BioCapital, SymBiosis, and Wellington Partners|
|2020-11-19||Imago BioSciences||Series C||$80M||Amgen Ventures, BlackRock, Blackstone, Farallon Capital Management, Frazier Healthcare Partners, Greenspring Associates, HighLight Capital, Kingdon Capital Management, MRL Ventures, Omega Fund Management, Pharmaron, Surveyor Capital, T. Rowe Price, and Xeraya Capital|
|2020-11-09||Prometheus Biosciences||Series D||$130M||AGI Partners, Cedars-Sinai Medical Center, Cormorant Capital, Cowen, Eventide Asset Management, Nestle, Perceptive Advisors, Point72 Asset Management, and RTW Investments|
|2020-07-28||Praxis Precision Medicines||Series C - II||$110M||Adage Capital Management, Ample Plus Fund, Avoro Capital Advisors, Blackstone, Cormorant Asset Management, Eventide Asset Management, Novo Holdings, OCV Partners, Point72 Ventures, Qatar Investment Authority, Surveyor Capital, Verition Fund Management, and Vida Ventures|
|2020-06-30||Goldfinch Bio||Series B||$100M||Ally Bridge Group, BlackRock, Casdin Capital, Eventide Asset Management, Gilead Sciences, Schroder Adveq, Undisclosed Investors, Wellington Management, and Yonjin Venture|